Last updated on January 2020

Treat_CCM: Propranolol in Cerebral Cavernous Malformation


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Cerebral Cavernous Malformation
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Patients with Familial cerebral cavernous malformations (FCCM);
  2. history of clinical symptoms or events: intracerebral hemorrhage, stroke, permanent or transient focal deficits, seizures, disability or any other neurological symptom supposedly related to CCM;
  3. age of at least 18 years.
  4. Written informed consent to participate in the study prior to any study procedures.

Exclusion Criteria:

  1. Implanted pacemaker or any other condition preventing the magnetic resonance imaging (MRI);
  2. bradycardia (<50 bpm) or 2nd or 3rd degree AV block, hypotension (symptomatic);
  3. unstable diabetes;
  4. severe asthma;
  5. renal and/or liver failure;
  6. current use of verapamil and diltiazem for risk of excessive bradycardia;
  7. previous brain surgery (within 6 months);
  8. known hypersensitivity to study drug (propranolol or any of the ingredients)
  9. pregnant or lactating women or women of childbearing potential who are not protected from pregnancy by an accepted method of contraception
  10. participation to another clinical trial;
  11. inability to cooperate with the trial procedures.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.